Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Dual Energy THERMOCOOL SMARTTOUCH SF DE STSF catheter used with the TRUPULSE generator for treating ventricular arrhythmias, which are abnormal heart rhythms. This study focuses on whether the catheter and generator system can successfully treat these arrhythmias while following a specific procedural workflow during cardiac ablation. Participant safety is also closely monitored after the procedure to check for any complications. Participants with premature ventricular complexes PVC, sustained monomorphic ischemic ventricular tachycardia SMIVT, or sustained monomorphic non-ischemic ventricular tachycardia SMNIVT will undergo catheter ablation using the DE STSF catheter and TRUPULSE generator. The treatment involves delivering radiofrequency and pulsed field energy primarily as stacking applications, following the studys procedural workflow. This is a single-group interventional study assessing the catheter and generator combination. During the study, participants will be monitored for effectiveness at 3 months for PVC and at 6 months for SMIVT and SMNIVT after the ablation procedure. Safety monitoring includes checking for primary adverse events up to 7 days post-procedure and serious adverse device effects and other adverse events up to 6 months. Various intraoperative measurements such as procedure time, mapping, ablation parameters, and anesthesia type will also be recorded. Overall, participants will be followed until the primary completion date, which is up to about 15 months from study start.
Actively Recruiting
Researchers are collecting clinical data to evaluate the ongoing safety and performance of commercially approved Biosense Webster Inc. BWI medical devices used during routine cardiac arrhythmia mapping and ablation procedures. This observational study aims to confirm the safety and effectiveness of these devices in real-world settings and expand knowledge about their use in treating cardiac arrhythmias such as atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia. Participants diagnosed with cardiac arrhythmias who are scheduled for catheter ablation using BWI therapeutic catheters, including Varipulse Catheter and Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, will be observed during their routine clinical care. No specific interventions are assigned by the study instead, participants undergo standard treatment with these devices as part of their medical management. During the study, participants will be monitored for adverse events related to the devices and procedures, both shortly after ablation and up to one year. Researchers will track arrhythmia outcomes and repeated procedures as part of routine follow-up. Data collection includes safety assessments, arrhythmia recurrence, and hospitalization events. Participation may last up to a year, with ongoing observation during routine healthcare visits.
Actively Recruiting
This research aims to assess the effectiveness and safety of adding oral anticoagulation OAC to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation POAF after isolated coronary artery bypass graft CABG surgery. The study is a prospective, multicenter, open-label, randomized trial comparing OAC with no OAC to evaluate the prevention of thromboembolic events and the risk of major bleeding. Participants are randomly assigned to either an OAC-based strategy using vitamin K antagonists or approved direct oral anticoagulants alongside antiplatelet therapy, or to an antiplatelet-only strategy. The anticoagulation treatment lasts for 90 days, with option for crossover to OAC if recurrent atrial fibrillation occurs after 30 days in the control group. Up to 500 patients may also participate in a digital health substudy using a wearable heart rhythm monitor for 30 days post-discharge. During the study, participants have follow-up visits at 30, 60, 90, and 180 days after randomization, including phone contacts and clinical assessments. Researchers will monitor outcomes such as death, stroke, transient ischemic attacks, myocardial infarction, thromboembolism, and bleeding events up to 180 days. Data from patients who decline randomization are collected in a parallel registry to compare baseline risk and treatment strategies.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sovateltide, a new drug candidate, in treating patients with acute cerebral ischemic stroke. This type of stroke occurs when a blood clot blocks blood flow to the brain, causing damage to brain cells. The study builds on earlier clinical trials in India that showed promising results in improving neurological function and recovery with sovateltide, encouraging further testing in the United States and other countries. The trial compares sovateltide combined with standard care against a placebo normal saline plus standard care. Participants will receive three intravenous doses of sovateltide or placebo on days 1, 3, and 6 after stroke onset. Each dose is given as a one-minute IV bolus within 24 hours of stroke symptoms beginning. The study is randomized, double-blind, and placebo-controlled to rigorously assess the treatments impact. Participants will be monitored for 90 days after receiving treatment. Researchers will use several scales to evaluate recovery, including the modified Rankin Scale to measure disability, the National Institutes of Health Stroke Scale for neurological function, and the Barthel Index for daily living activities. Quality of life assessments and cognitive tests will also be done. Safety is closely watched for any adverse events or complications during the study period. The total participation time is about three months following treatment.
Actively Recruiting
Atrial fibrillation is the most common heart rhythm disorder, increasing the risk of blood clots forming in the heart, especially in the left atrium. These clots can cause strokes if they travel to the brain. Patients with atrial fibrillation who have had an intracranial bleed bleeding in the brain are often treated with blood thinners to prevent stroke, but these medications can increase bleeding risk. This study compares two treatment methods to prevent strokes in such patients blood thinners and a device that closes off the left atrial appendage of the heart. The study randomly assigns participants to one of two groups. One group receives a device called Watchman or Watchman FLX to close the left atrial appendage through a minimally invasive procedure, followed by short-term blood thinning medication. The other group receives standard oral blood thinners as per current guidelines. Only approved drugs and devices are used. The trial aims to provide data to help doctors manage patients with atrial fibrillation who have experienced brain bleeds. Participants are followed for up to three years after randomization. Researchers monitor for events such as death from cardiovascular causes, stroke, systemic embolism, and bleeding episodes. Assessments include imaging during the procedure and regular follow-up visits to track health outcomes. The main measure is event-free survival without these complications. This long-term follow-up helps evaluate the safety and effectiveness of each treatment approach in preventing strokes and bleeding.
Actively Recruiting
Researchers are studying dementia and mild cognitive impairment in Bavaria, focusing on people living at home with these conditions and their family caregivers. This study aims to improve understanding of the complexity, progression, and care needs of dementia in both urban and rural areas. The research includes people with mild cognitive impairment and mild to moderate dementia as defined by ICD-10 codes and is conducted through a multicenter, prospective, longitudinal registry. Participants include those with mild cognitive impairment or dementia and their family caregivers. Before joining, cognitive tests such as the Mini Mental State Examination and Montreal Cognitive Assessment are used to assess suitability. Participants are interviewed face-to-face at the start, after 6 months, 12 months, and then annually. Recruitment is through various institutions involved in dementia care, including clinics, counseling centers, and outpatient and inpatient facilities across Bavaria. During the study, participants provide detailed information on demographics, health, social and care situations, cognitive assessments, and quality of life measures at multiple timepoints over several years. Researchers collect data on medical history, medication use, cognitive function, social support, internet use, mobility, caregiver burden, and more. This long-term observation helps track changes and care needs up to ten years, with regular follow-up interviews and assessments throughout the study.
Actively Recruiting
Researchers are investigating a new nationwide care model called NVF to improve the diagnosis and treatment of patients with recent-onset stable chest pain and suspected coronary artery disease CAD in Germany. This study aims to enhance the use of coronary computed tomography CT as an alternative to cardiac catheterisation, potentially reducing cardiovascular events like heart attacks and strokes while lowering healthcare costs. The trial is a pragmatic, cluster-randomised stepped-wedge design conducted in 16 regions across Germany. Participants will be assigned to one of two groups usual care following national guidelines without structured coordination, or the IMPRO cross-sectoral care model that connects general practitioners with certified cardiac CT centres. The IMPRO program includes evidence-based initial assessments, shared decision-making among doctors and patients, quality-assured CT imaging, structured reporting, and ongoing training and quality monitoring at participating sites. This intervention is designed to improve diagnostic accuracy and care coordination. During the study, participants will be monitored for major adverse cardiovascular events MACE such as cardiovascular death, myocardial infarction, or stroke over 12 months, with extended follow-up up to 5 years. Researchers will also track procedure-related complications, test rates, hospitalizations, emergency visits, radiation exposure, quality of life, angina symptoms, and medical costs. Data collection includes baseline and follow-up assessments at 3 months, 12 months, and 5 years to evaluate clinical outcomes, safety, cost-effectiveness, and patient quality of life.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
This research aims to evaluate the long-term outcomes, performance, and ongoing safety of the BIOMONITOR III and its possible successors in everyday clinical use. It focuses on patients with conditions such as tachycardia, atrial fibrillation, syncope, bradycardia, or cryptogenic stroke. The study is designed as an observational registry, allowing additional scientific investigations with minimal extra effort for participants and study sites. Participants will receive a BIOTRONIK Implantable Cardiac Monitor ICM and will use the CardioMessenger device to support the BIOTRONIK Home Monitoring system. The registry monitors patients under routine clinical care without introducing experimental treatments or interventions. Data collection includes the insertion procedure and success rate of the device, as well as the time taken to reach a relevant diagnosis starting from device implantation. Throughout the study, participants will be observed during their regular clinical care visits. Researchers will collect information on device performance, safety, and diagnostic timelines. The study will continue until August 30, 2027, tracking patient outcomes over this extended period. Participation involves consenting to the use of home monitoring technology and agreeing to data collection related to the implanted device and clinical events.
Actively Recruiting
Researchers are evaluating ways to prevent sudden cardiac death in patients with poor heart function after a heart attack myocardial infarct. The trial compares the use of an electrophysiology study EPS to guide early implantable cardioverter-defibrillator ICD implantation within 40 days after a heart attack, against standard care. The study also examines whether cardiac MRI CMR can predict dangerous heart rhythms and assess heart tissue damage early after a heart attack. Participants are randomly assigned to one of two groups. In the intervention group, all patients receive an early EPS those with certain types of inducible heart rhythms receive an ICD implant, while others do not. The control group receives standard care, which may include ICD implantation after 40 or 90 days if indicated by current guidelines. Some patients in both groups will have a CMR scan more than 48 hours after revascularization to study heart function, scarring, and tissue health. Participants will be followed for 2 years to monitor for sudden cardiac death or non-fatal heart rhythm problems, which is the main outcome. Other outcomes include overall survival, heart failure, repeat heart attacks, and issues related to ICD use. The study collects detailed heart rhythm and imaging data to better understand risks and improve treatment decisions for patients after a heart attack.
1-10 of 14
1